These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21983493)

  • 41. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype.
    Johnson SC; La Rue A; Hermann BP; Xu G; Koscik RL; Jonaitis EM; Bendlin BB; Hogan KJ; Roses AD; Saunders AM; Lutz MW; Asthana S; Green RC; Sager MA
    Alzheimers Dement; 2011 Jul; 7(4):456-65. PubMed ID: 21784354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals.
    Cacciaglia R; Molinuevo JL; Falcón C; Sánchez-Benavides G; Gramunt N; Brugulat-Serrat A; Esteller M; Morán S; Fauria K; Gispert JD;
    Neuroimage Clin; 2019; 23():101818. PubMed ID: 30991302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele.
    Padayachee ER; Zetterberg H; Portelius E; Borén J; Molinuevo JL; Andreasen N; Cukalevski R; Linse S; Blennow K; Andreasson U
    Brain Res; 2016 Nov; 1651():11-16. PubMed ID: 27653981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.
    Langbaum JB; Chen K; Caselli RJ; Lee W; Reschke C; Bandy D; Alexander GE; Burns CM; Kaszniak AW; Reeder SA; Corneveaux JJ; Allen AN; Pruzin J; Huentelman MJ; Fleisher AS; Reiman EM
    Arch Neurol; 2010 Apr; 67(4):462-8. PubMed ID: 20385913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes.
    Operto G; Cacciaglia R; Grau-Rivera O; Falcon C; Brugulat-Serrat A; Ródenas P; Ramos R; Morán S; Esteller M; Bargalló N; Molinuevo JL; Gispert JD;
    Alzheimers Res Ther; 2018 May; 10(1):48. PubMed ID: 29793545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
    Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
    J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population.
    Monge-Argilés JA; Gasparini-Berenguer R; Gutierrez-Agulló M; Muñoz-Ruiz C; Sánchez-Payá J; Leiva-Santana C
    Biomed Res Int; 2016; 2016():1390620. PubMed ID: 27092308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
    Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
    Han MR; Schellenberg GD; Wang LS;
    BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
    Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia.
    McGuinness B; Carson R; Barrett SL; Craig D; Passmore AP
    Neurosci Lett; 2010 Oct; 483(1):62-6. PubMed ID: 20678545
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes.
    Linnertz C; Anderson L; Gottschalk W; Crenshaw D; Lutz MW; Allen J; Saith S; Mihovilovic M; Burke JR; Welsh-Bohmer KA; Roses AD; Chiba-Falek O
    Alzheimers Dement; 2014 Sep; 10(5):541-51. PubMed ID: 24439168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical studies of poly-T variants in the Alzheimer's disease associated TOMM40 gene.
    Hedskog L; Brohede J; Wiehager B; Pinho CM; Revathikumar P; Lilius L; Glaser E; Graff C; Karlström H; Ankarcrona M
    J Alzheimers Dis; 2012; 31(3):527-36. PubMed ID: 22596268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.
    Roses AD; Lutz MW; Amrine-Madsen H; Saunders AM; Crenshaw DG; Sundseth SS; Huentelman MJ; Welsh-Bohmer KA; Reiman EM
    Pharmacogenomics J; 2010 Oct; 10(5):375-84. PubMed ID: 20029386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intrinsic functional connectivity alterations in cognitively intact elderly APOE ε4 carriers measured by eigenvector centrality mapping are related to cognition and CSF biomarkers: a preliminary study.
    Luo X; Qiu T; Jia Y; Huang P; Xu X; Yu X; Shen Z; Jiaerken Y; Guan X; Zhou J; Zhang M;
    Brain Imaging Behav; 2017 Oct; 11(5):1290-1301. PubMed ID: 27714554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD.
    Sjögren M; Rosengren L; Minthon L; Davidsson P; Blennow K; Wallin A
    Neurology; 2000 May; 54(10):1960-4. PubMed ID: 10822437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.